Clinical Trial Update: Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gefitinib after complete surgical removal of stage IB to IIIA non-small cell lung cancer; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Adenosquamous Cell Lung Cancer
• Bronchioloalveolar Carcinoma
• Large Cell Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-01-01